THE PMD-200 (pain Monitoring Device)

Leveraging patented NOL™ technology, the PMD-200™, is a pain monitoring device, that quantifies patients’ physiological response to pain.

By using the PMD-200™ in operating rooms and critical care units, where patients under general anesthesia are unable to communicate their pain, clinicians are able to assess nociception, and titrate analgesic medications – avoiding excessive use or underuse that may result in significant complications.

PMD-200™ is a simple to use, stand alone monitor.

MEDASENSE_PMD200_VIDEO_1-2017

how does it work?

Medasense-PMD-200-operating room

The system consists of a non-invasive finger probe and sensors that acquire multiple physiological signals.

Artificial intelligence algorithms process and analyze dozens of pain-related physiological parameters and derivatives.  The information is converted into a real-time index- NOL™ (Nociception Level) Index, presented on the PMD-200™ bedside monitor.

NOL™ Index varies on a scale where 0 represents no pain (anti nociception) and 100 represents extreme pain (nociception). The NOL™ index delivers accurate, continuous, and non-invasive nociception monitoring.

Medasense NOL (Nociception Level) Index scale

PMD-200TM is CE marked. Not available in the U.S.

OEM Solutions

Medasense’s nociception monitoring technology can be implemented in standalone devices offered by the company or integrated into third-party medical devices.

Medasense-multi-parameters

what Experts Say

"It is clear that current pain assessment approaches in the operating room are limited. The NOL™ index provides anesthesiologists with a decision support tool to objectively assess and optimize the treatment of a patient’s nociception pain."

Prof. Albert Dahan, MD, Ph.D., Department of Anaesthesiology, Leiden University Medical Center, The Netherlands, Principal Investigator.

"Getting the right dose of anti-nociceptive medications matters. Too little, and patients wake up in pain. Too much, and patients are at risk of drug-related complications."

Dr. Daniel Sessler, Head of Department of Outcomes Research, Cleveland Clinic, Ohio, USA. A member of Medasense’s advisory board.

"I truly believe in the NOL™ technology. I am convinced it will improve the quality of our anesthesia and impact on patients' recovery."

Dr. Philippe Richebé is Professor and Anesthesiologist at Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, Canada. Principal Investigator, Member of Medasense’s advisory board.

"Our study confirmed that the NOL™ gives a better assessment of the patient’s nociceptive state than the parameters we currently use in the operating theatre."

Dr. Ruth Edry, Department of Anesthesiology, Rambam Medical Centre, Haifa, Israel.

PRODUCT ENQUIRY / BECOME A DISTRIBUTOR / OEM COLLABORATION